Skip to main content

Table 3 The biomarker levels in the two categories (HS/NHS) of patients

From: Serological biomarker testing helps avoiding unnecessary endoscopies in obese patients before bariatric surgery

  Whole Series Healthy stomach (HS Group)
n = 22
Non-healthy stomach (NHS Group)
n = 43
(p-value)#
aG17b pmol/l mean ± SD (range) 3.9 ± 5.0
(0–28.1)
2.05 ± 2.2
(0–9.9)
4.9 ± 5.7
(0–28.1)
0.028
bG17 s pmol/l mean ± SD (range) 12.3 ± 10.3
(0–40.9)
8.8 ± 8.4
(0.2–36.1)
14.1 ± 10.8
(0–40.9)
0.048
PG I μg/I mean ± SD (range) 81.8 ± 38.6
(22.7–197.5)
58.2 ± 27.9
(33.0–151.1)
93.9 ± 38.0
(22.7–197.5)
< 0.0001
PG II μg/I mean ± SD (range) 7.2 ± 5.9
(0.3–29.3)
3.37 ± 1.7
(0.3–8.4)
9.2 ± 6.4
(1.4–29.3)
< 0.0001
PG I/PG II mean ± SD (range) 15.5 ± 12.3
(3.3–103.3)
21.6 ± 18.9
(10.7–103.3)
12.4 ± 4.6
(3.2–25.2)
< 0.0001
IgG EIU mean ± SD (range) 64.2 ± 40.8
(2.1–121.1)
13.12 ± 7.7
(2.1–27.3)
90.4 ± 21.1
(38.1–121.1)
< 0.0001
  1. a G-17b, basal gastrin-17
  2. b G-17 s, stimulated gastrin-17
  3. #Mann-Whitney U-Test